EXPLAINABLE MACHINE LEARNING FOR NON-INVASIVE PROSTATE CANCER DETECTION USING SIGNAL-DERIVED VOC FEATURES

Authors

  • Settawut Chalermwat Institute of Medicine, Suranaree University of Technology
  • Chatiwat Piyarom School of Surgery, Institute of Medicine, Suranaree University of Technology
  • Watcharapong Anakkamatee Department of Mathematics, Faculty of Science, Naresuan University https://orcid.org/0009-0003-4803-5245
  • Anawin Pechbooranin School of Mechatronics Engineering, Institute of Engineering, Suranaree University of Technology https://orcid.org/0009-0005-1438-7319
  • Sekdusit Aekgawong School of Surgery, Institute of Medicine, Suranaree University of Technology https://orcid.org/0009-0008-9387-9611

DOI:

https://doi.org/10.55766/sujst11714

Keywords:

Interpretable machine learning, Naïve Bayes classifier, Prostate cancer, Urinary biomarkers, Volatile organic compounds (VOCs)

Abstract

The present study aimed to develop an explainable artificial intelligence (AI) model by using urinary volatile organic compound (VOC) profiles for non-invasive prostate cancer (PCa) detection. A total of 123 participants were included: 29 with PCa, 67 with benign prostatic hyperplasia (BPH), and 27 healthy controls. Urinary VOC signals were recorded by metal oxide semiconductor sensors across six thermal cycles, generating 120 features per subject. Mutual Information and Random Forest importance identified 15 key features. Five classifiers-logistic regression (LR), decision tree (DT), random forest (RF), naïve Bayes (NB), and ensemble voting (EV) were optimized with GridSearchCV and evaluated by using stratified cross-validation with SMOTE. The NB classifier provided the best discriminative performance on the independent test set, achieving an ROC-AUC of 0.90, while its accuracy, precision, recall, and F1-score were comparable to those of LR and RF under stratified 5-fold cross-validation. Importantly, explainability in this model arises from the probability-based decision structure of NB, which generates two distinctly separated probability clusters for PCa and non-PCa. This bimodal distribution enables direct interpretation of risk estimates, offering transparent and easy-to-communicate clinical meaning an advantage over black-box models. LR showed comparable utility (ROC-AUC = 0.81), whereas RF (0.76) and EV (0.77) demonstrated moderate discriminative performance, and DT produced the weakest results (0.67). These findings indicate that urinary VOC-derived features, analyzed with interpretable AI, can differentiate PCa from benign and control cases with reproducible performance across cross-validation folds. NB emerged as the most robust and transparent approach in this study, supporting the potential of VOC-based AI as a low-cost adjunct to clinical assessment and diagnostic pathways. Multi-center validation is recommended to confirm generalizability.

References

Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha, M., Mackenzie, G. R., Leung, H. Y., & Dufès, C. (2018). Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12. Drug Delivery, 25(1), 679-689. https://doi.org/10.1080/10717544.2018.1440666

Babaian, R. J., Toi, A., Kamoi, K., Troncoso, P., Sweet, J., Evans, R., Johnston, D., & Chen, M. (2000). A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. The Journal of Urology, 163(1), 152-157. https://doi.org/10.1016/S0022-5347(05)67993-1

Chen, J., Zhang, D., Yan, W., Yang, D., & Shen, B. (2013). Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. BioMed Research International, 2013, 901578. https://doi.org/10.1155/2013/901578

Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010). Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer, 46(4), 765-781. https://doi.org/10.1016/j.ejca.2009.12.014

Gao, Q., Su, X., Annabi, M. H., Schreiter, B. R., Prince, T., Ackerman, A., Morgas, S., Mata, V., Williams, H., & Lee, W.-Y. (2019). Application of urinary volatile organic compounds (VOCs) for the diagnosis of prostate cancer. Clinical Genitourinary Cancer, 17(3), 183-190. https://doi.org/10.1016/j.clgc.2019.02.003

Halloran, P. F., Kreepala, C., Einecke, G., Loupy, A., & Sellarés, J. (2015). Therapeutic approaches to organ transplantation. In Molecular pathology of kidney disease (pp. 184-216). Wiley. https://doi.org/10.1002/9781119072997.ch10

Johns, L. E., & Houlston, R. S. (2003). A systematic review and meta-analysis of familial prostate cancer risk. BJU International, 91(9), 789-794. https://doi.org/10.1046/j.1464-410X.2003.04232.x

Kreepala, C., Ayutaya, V. S. N., Phatthanakun, R., Thabsuwan, K., & Paewponsong, J. (2025). The biosensor using the target urine volatile organic compounds for detecting diabetic kidney disease. Scientific Reports, 15(1), 14738. https://doi.org/10.1038/s41598-025-00013-6

Kreepala, C., Kitporntheranunt, M., Sangwipasnapaporn, W., Rungsrithananon, W., & Wattanavaekin, K. (2018). Assessment of preeclampsia risk by use of serum ionized magnesium-based equation. Renal Failure, 40(1), 99-106. https://doi.org/10.1080/0886022X.2017.1422518

Kreepala, C., Panpruang, P., Yodprom, R., Piyajarawong, T., Wattanavaekin, K., Danjittrong, T., & Phuthomdee, S. (2021). Manifestation of rs1888747 polymorphisms in the FRMD3 gene in diabetic kidney disease and diabetic retinopathy in type 2 diabetes patients. Kidney Research and Clinical Practice, 40(2), 263-271. https://doi.org/10.23876/j.krcp.20.190

Kreepala, C., Sangpanich, A., Boonchoo, P., & Rungsrithananon, W. (2017). Measurement accuracy of total cell volume by automated dialyzer reprocessing: A prospective cohort study. Annals of Medicine and Surgery, 18, 16-23. https://doi.org/10.1016/j.amsu.2017.04.019

Kreepala, C., Srila-On, A., Kitporntheranunt, M., Anakkamatee, W., Lawtongkum, P., & Wattanavaekin, K. (2019). The association between GFR evaluated by serum cystatin C and proteinuria during pregnancy. Kidney International Reports, 4(6), 854-863. https://doi.org/10.1016/j.ekir.2019.04.004

Li, N., Wu, X., Zhuang, W., Xia, L., Chen, Y., Wu, C., Rao, Z., Du, L., Zhao, R., Yi, M., Wan, Q., & Zhou, Y. (2021). Tomato and lycopene and multiple health outcomes: Umbrella review. Food Chemistry, 343, 128396. https://doi.org/10.1016/j.foodchem.2020.128396

Liu, Q., Fan, Y., Zeng, S., Zhao, Y., Yu, L., Zhao, L., Gao, J., Zhang, X., & Zhang, Y. (2023). Volatile organic compounds for early detection of prostate cancer from urine. Heliyon, 9(6), Article e16686. https://doi.org/10.1016/j.heliyon.2023.e16686

Ozah, E., & Imasogie, D. E. (2023). The diagnostic accuracy of prostate-specific antigen and digital rectal examination in the diagnosis of prostate cancer at the University of Benin Teaching Hospital. Journal of West African College of Surgeons, 13(3), 91-95. https://doi.org/10.4103/jwas.jwas_32_23

Parra-Soto, S., Ahumada, D., Petermann-Rocha, F., Boonpoor, J., Gallegos, J. L., Anderson, J., Sharp, L., Malcomson, F. C., Livingstone, K. M., Mathers, J. C., Pell, J. P., Ho, F. K., & Celis-Morales, C. (2022). Association of meat, vegetarian, pescatarian and fish-poultry diets with risk of 19 cancer sites and all cancer: Findings from the UK Biobank prospective cohort study and meta-analysis. BMC Medicine, 20(1), 79. https://doi.org/10.1186/s12916-022-02257-9

Presti, J. C., O’Dowd, G. J., Miller, M. C., Mattu, R., & Veltri, R. W. (2003). Extended peripheral zone biopsy schemes increase cancer detection rates. The Journal of Urology, 169(1), 125-129. https://doi.org/10.1016/S0022-5347(05)64051-7

Rowles, J. L., Ranard, K. M., Applegate, C. C., Jeon, S., An, R., & Erdman, J. W., Jr. (2018). Processed and raw tomato consumption and risk of prostate cancer. Prostate Cancer and Prostatic Diseases, 21(3), 319-336. https://doi.org/10.1038/s41391-017-0005-x

Rowles, J. L., Ranard, K. M., Smith, J. W., An, R., & Erdman, J. W., Jr. (2017). Increased dietary and circulating lycopene are associated with reduced prostate cancer risk. Prostate Cancer and Prostatic Diseases, 20(4), 361-377. https://doi.org/10.1038/pcan.2017.25

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 72(1), 7-33. https://doi.org/10.3322/caac.21708

Suthat Na Ayutaya, V., Tantisatirapoon, C., Aekgawong, S., Anakkamatee, W., Danjittrong, T., & Kreepala, C. (2024). Urinary cancer detection by the target urine volatile organic compounds biosensor platform. Scientific Reports, 14(1), 3551. https://doi.org/10.1038/s41598-024-54138-1

Tangkiatkumjai, M., & Kreepala, C. (2018). General approach to evaluating beneficial and adverse effects of CAM use in kidney diseases. In Complementary and alternative medicine and kidney health (pp. 60-99). IGI Global. https://doi.org/10.4018/978-1-5225-2882-1.ch004

Downloads

Published

2026-08-21

How to Cite

Chalermwat, S., Piyarom, C., Anakkamatee, W., Pechbooranin, A., & Aekgawong, S. (2026). EXPLAINABLE MACHINE LEARNING FOR NON-INVASIVE PROSTATE CANCER DETECTION USING SIGNAL-DERIVED VOC FEATURES. Suranaree Journal of Science and Technology, 33(4), 030405(1–9). https://doi.org/10.55766/sujst11714